About Elekta Xoft
Elekta Xoft is a Healthcare company based in Sunnyvale (United States) founded in 1998, and was acquired by Elekta in October 2023. It operates as an electronic brachytherapy systems are developed for cancer treatment. It operates on a Professional Services and Direct-to-Consumer (D2C) model. Elekta Xoft has raised $116.53 million across 7 funding rounds from investors including Elekta, Frazier Healthcare Partners and Tekla Capital Management. Elekta Xoft offers products and services including Elekta Xoft Axxent Electronic Brachytherapy System, Breast eBx, Skin eBx, and GYN eBx. Its focus areas include Medical Devices and Radiation Therapy Equipment. Its legal entity is Elekta. Its competitors include Koya Medical, Sensus Healthcare, Theragenics, Eckert & Ziegler BEBIG and Concure Oncology and 3 more; 7 of its 8 listed competitors have raised funding.
Company details
Elekta Xoft, a division of Elekta, is engaged in providing advanced electronic brachytherapy (eBx) systems for cancer care. The companys solutions are designed to deliver precise, low-energy, high-dose-rate radiation therapy in various clinical settings without the need for extensive shielding or bunkers. Applications include treatments for early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers. The portable and flexible design of the Elekta Xoft Axxent system allows it to be used in diverse environments, from outpatient rooms to operating theaters, expanding access to targeted radiation therapy. The company operates within the healthcare sector, focusing on innovative medical devices and radiation therapy equipment.
Products & Services of Elekta Xoft
Elekta Xoft offers a comprehensive portfolio of products and services, including Elekta Xoft Axxent Electronic Brachytherapy System, Breast eBx, Skin eBx, and GYN eBx.
Portable system for targeted radiation in clinical settings.
Immediate radiation treatment delivered to breast tumor bed.
Non-invasive radiation treatment for non-melanoma skin cancer.
Targeted radiation therapy for gynecological cancer treatment.
Apps and channels of Elekta Xoft
its YouTube channel Elekta has 11K subscribers and 30 videos.
Videos from Elekta Xoft
The most watched videos on Elekta Xoft's YouTube channel, Elekta (11K subscribers). Click a video to play it here.
More on Elekta.
Funding Insights of Elekta Xoft
Elekta Xoft has successfully raised a total of $116.53M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $804.53 thousand completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $116.53M
- Total Rounds 7
- Last Round Debt – Conventional — $804,525
- First Round $18M
(Jun 2003)
- Investors Count 12
All 7 funding rounds of Elekta Xoft with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2010 | $804,525 | Debt – Conventional | – | – | – |
| Jul 2010 | $968,055 | Debt – Conventional | – | – | – |
| Jun 2009 | $10.33M | Series E | – | – | – |
| Aug 2008 | $25M | Series E | – | – | |
| Apr 2007 | $33.2M | Series D | – | – | |
| May 2005 | $30M | Series C | – | – | |
| Jun 2003 | $18M | Series B | – | – | – |
14 investors in total: 14 institutional.
Investors in Elekta Xoft
Elekta Xoft has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Elekta, Frazier Healthcare Partners and Tekla Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in the US | – | cgp.com | Chicago, United States | |
- | – | eastoncapital.com | - | |
Early-stage tech and life-sciences firms are funded across the US. | – | maverickventures.com | San Francisco, United States | |
VC firm investing in the US | – | shv.com | Palo Alto, United States | |
Growth & late stage life sciences and tech focused venture capital firm funding companies in the US | – | mosaixventures.com | Chicago, United States | |
Investments are directed by FMG toward biotechnology and related sectors. | 1979 | frantzgroup.com | Mentor, United States | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Early, mid, and late-stage investments are made in science sectors. | – | newscienceventures.com | New York, United States | |
US healthcare companies are invested in stage-agnostically by Cutlass Capital. | – | cutlasscapital.com | Boston, United States | |
- | – | rivervest.com | - |
Investor details for Elekta Xoft
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Elekta Xoft
Competitors of Elekta Xoft
Elekta Xoft has 8 listed competitors in our database, 7 of them funded. They include Koya Medical, Sensus Healthcare, Theragenics, Eckert & Ziegler BEBIG and Concure Oncology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| koyamedical.com | 2018 | Oakland, United States | $37.02M | 122 | Provider of smart wearable compression technology for lymphedema and venous diseases | |
| sensushealthcare.com | 2010 | Boca Raton, United States | $12.24M | 42 | Non-invasive skin cancer treatments are developed and marketed. | |
| theragenics.com | 1981 | Buford, United States | $9.44M | 566 | Manufacturer of surgical products and brachytherapy devices | |
| bebig.com | 1997 | Seneffe, Belgium | – | – | Brachytherapy devices are developed for prostate, breast, and gynecological cancers. | |
| breastmicroseed.com | 2014 | Mercer Island, United States | $14.04M | – | Breast microseed radiotherapy for early-stage breast cancer is developed. | |
| c4imaging.com | 2009 | Bellaire, United States | $7.35M | – | Image-guided procedures for prostate cancer treatment are provided. | |
| civatechoncology.com | 2006 | Durham, United States | $12.4M | – | Polymer-based devices for low-dose brachytherapy in solid tumors are provided. | |
| radiogel.com | 2006 | Richland, United States | $725,000 | – | Yttrium-90 brachytherapy devices for cancer treatment are developed. |
Detailed competitors of Elekta Xoft
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as Elekta Xoft (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Elekta Xoft
Complete news archive for Elekta Xoft
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elekta Xoft
Elekta Xoft was founded in 1998 and raised its 1st funding round 5 years after it was founded.
Elekta Xoft is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Elekta Xoft is a funded company, having raised a total of $116.53M across 7 funding rounds to date. The company's 1st funding round was a Series B of $18M, raised on Jun 2003.
Elekta Xoft, a division of Elekta, is engaged in providing advanced electronic brachytherapy (eBx) systems for cancer care. The companys solutions are designed to deliver precise, low-energy, high-dose-rate radiation therapy in various clinical settings without the need for extensive shielding or bunkers. Applications include treatments for early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers. The portable and flexible design of the Elekta Xoft Axxent system allows it to be used in diverse environments, from outpatient rooms to operating theaters, expanding access to targeted radiation therapy. The company operates within the healthcare sector, focusing on innovative medical devices and radiation therapy equipment.
Elekta Xoft's top competitors include Koya Medical, Sensus Healthcare and RadioGel.
Elekta Xoft offers Elekta Xoft Axxent Electronic Brachytherapy System, Breast eBx, Skin eBx, and GYN eBx.
Elekta Xoft has 14 investors. Key investors include Elekta, Frazier Healthcare Partners, Tekla Capital Management, iCAD, and Frantz Medical.
Elekta Xoft operates through Elekta.
Yes. Elekta Xoft was acquired by iCAD in December 2010.